This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Studies of the Ocular Complications of AIDS (SOCA)--Monoclonal Antibody CMV Retinitis Trial (MACRT) (MACRT)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Johns Hopkins Bloomberg School of Public Health
ClinicalTrials.gov Identifier:
NCT00000135
First received: September 23, 1999
Last updated: October 14, 2015
Last verified: July 2015
Results First Received: June 12, 2015  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Participant, Care Provider);   Primary Purpose: Treatment
Conditions: HIV Infections
Cytomegalovirus Retinitis
Interventions: Drug: MSL-109
Other: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Randomization was stratified on the basis of whether patients had untreated or relapsed retinitis. Primary drug therapy for CMV retinitis was determined by the treating physician.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Two hundred and nine patients with acquired immunodeficiency syndrome and active CMV retinitis were enrolled in a multicenter, phase 2/3, randomized, placebo controlled clinical trial. Patients received adjuvant treatment with MSL-109, 60mg intravenously every 2 weeks, or placebo,.

Reporting Groups
  Description
MSL-109

The dose MSL-109 administered by intravenous infusion every 2 weeks 60 mg.

MSL-109: 60 mg, IV (in vein) every two weeks, treatment continued until death or common closeout.

Placebo

Placebo administered intravenous infusion every 2 weeks 60 mg.

MSL-109: 60 mg, IV (in vein) every two weeks, treatment continued until death or common closeout.


Participant Flow:   Overall Study
    MSL-109   Placebo
STARTED   104   105 
COMPLETED   77   91 
NOT COMPLETED   27   14 
Death                27                14 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
MSL-109

The dose MSL-109 administered by intravenous infusion every 2 weeks 60 mg.

MSL-109: 60 mg, IV (in vein) every two weeks, treatment continued until death or common closeout.

Placebo

Placebo administered intravenous infusion every 2 weeks 60 mg.

MSL-109: 60 mg, IV (in vein) every two weeks, treatment continued until death or common closeout.

Total Total of all reporting groups

Baseline Measures
   MSL-109   Placebo   Total 
Overall Participants Analyzed 
[Units: Participants]
 104   105   209 
Age 
[Units: Participants]
     
<=18 years   0   0   0 
Between 18 and 65 years   104   105   209 
>=65 years   0   0   0 
Gender 
[Units: Participants]
     
Female   11   11   22 
Male   93   94   187 
Region of Enrollment 
[Units: Participants]
     
United States   104   105   209 


  Outcome Measures

1.  Primary:   Mortality Rate   [ Time Frame: All patients enrolled were followed for a 17 month period or until a common study closing date ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Curtis Meinert, PhD
Organization: Johns Hopkins University
phone: 410-955-8198
e-mail: cmeinert@jhsph.edu


Publications of Results:

Responsible Party: Johns Hopkins Bloomberg School of Public Health
ClinicalTrials.gov Identifier: NCT00000135     History of Changes
Other Study ID Numbers: NEI-34
Study First Received: September 23, 1999
Results First Received: June 12, 2015
Last Updated: October 14, 2015